Volume 21, Number 9—September 2015
Letter
Functional Immune Reconstitution by Interleukin-2 Adjunctive Therapy for HIV/Mycobacterial Co-infection
Figure
![Laboratory findings and drug treatment regimen over time for an HIV-infected patient with disseminated Mycobacterium tilburgii infection, December 2006–October 2014. Top graph shows CD4+ T cell count, HIV viral load, and use of interleukin-2 (IL-2; gray shading). Bottom graph shows antimycobacterial drug combinations, antiretroviral therapy (ART), and trimethorprim/sulfamethoxazole prophylaxis.](/eid/images/15-0461-F1.jpg)
Figure. Laboratory findings and drug treatment regimen over time for an HIV-infected patient with disseminated Mycobacterium tilburgii infection, December 2006–October 2014. A) CD4+ T cell count, HIV viral load, and use of interleukin-2 (IL-2; gray shading). B) antimycobacterial drug combinations, antiretroviral therapy (ART), and trimethoprim/sulfamethoxazole prophylaxis.
Page created: August 14, 2015
Page updated: August 14, 2015
Page reviewed: August 14, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.